These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448 [TBL] [Abstract][Full Text] [Related]
3. Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results. Hervé P; Cahn JY; Plouvier E; Flesch M; Tamayo E; Leconte des Floris R; Peters A Invest New Drugs; 1984; 2(2):245-52. PubMed ID: 6381384 [TBL] [Abstract][Full Text] [Related]
4. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557). Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155 [TBL] [Abstract][Full Text] [Related]
5. Mobilization of peripheral stem cells for transplantation. Nemunaitis J; Rosenfeld C J Hematother; 1993; 2(3):351-5. PubMed ID: 7921995 [No Abstract] [Full Text] [Related]
6. Incubation of autologous bone marrow graft with ASTA Z 7557: comparative studies of hematological reconstitution after purged or nonpurged bone marrow transplantation. Beaujean F; Hartmann O; Pico J; Parmentier C; Hayat M; Lemerle J; Duédari N Pediatr Hematol Oncol; 1987; 4(2):105-15. PubMed ID: 3152918 [TBL] [Abstract][Full Text] [Related]
7. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation. Hagenbeek A; Martens AC Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383 [TBL] [Abstract][Full Text] [Related]
8. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related]
9. Transplantation of non-purified autologous bone marrow in patients with AML in first remission. Löwenberg B; Abels J; van Bekkum DW; Dzoljic G; Hagenbeek A; Hendriks WD; van de Poel J; Sizoo W; Sintnicolaas K; Wagemaker G Cancer; 1984 Dec; 54(12):2840-3. PubMed ID: 6388819 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging. Singer CR; Linch DC Leuk Res; 1987; 11(11):953-9. PubMed ID: 3320579 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide. Jiang R; Bony V; Lopez M Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906 [No Abstract] [Full Text] [Related]
12. Autologous marrow transplantation in first remission acute myeloid leukemia using marrow purged with mafosfamide. Rizzoli V; Mangoni L; Carlo-Stella C; Carella AM; Coser P; Angrilli F; Porcellini A; Bernabei PA Bone Marrow Transplant; 1991; 7 Suppl 2():37. PubMed ID: 1878710 [No Abstract] [Full Text] [Related]
13. On the fate of leukemic cells infused with the autologous marrow graft. Hagenbeek A; Martens AC Haematol Blood Transfus; 1987; 30():553-9. PubMed ID: 3305218 [No Abstract] [Full Text] [Related]
15. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Douay L; Gorin NC; Laporte JP; Lopez M; Najman A; Duhamel G Invest New Drugs; 1984; 2(2):187-90. PubMed ID: 6381382 [TBL] [Abstract][Full Text] [Related]
16. Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation. Stewart FM; Kaiser DL; Ishitani KP; Pirsch GW; Niskanen E Exp Hematol; 1989 Oct; 17(9):974-80. PubMed ID: 2673831 [TBL] [Abstract][Full Text] [Related]
17. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia. Skala JP; Rogers PC; Chan KW; Rodriguez WC Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075 [No Abstract] [Full Text] [Related]
18. Kinetics of CFU-c population after autologous bone marrow graft. Herve P; Tamayo E; Lenys R; Peters A; Rozenbaum A; Floris RL Br J Haematol; 1979 Dec; 43(4):681-2. PubMed ID: 393297 [No Abstract] [Full Text] [Related]
19. Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells. Hagenbeek A; Martens AC Leukemia; 1989 Jul; 3(7):535-7. PubMed ID: 2659904 [TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation in patients with acute leukemia. Caramatti C; Mangoni L; Carlo-Stella C; Rizzoli V Acta Biomed Ateneo Parmense; 1993; 64(5-6):213-20. PubMed ID: 7992558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]